vs
NELNET INC（NNI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
NELNET INC的季度营收约是REGENXBIO Inc.的1.1倍（$33.5M vs $30.3M），NELNET INC净利率更高（172.3% vs -221.3%，领先393.6%），NELNET INC同比增速更快（79.6% vs 43.0%），NELNET INC自由现金流更多（$396.7M vs $-52.8M），过去两年NELNET INC的营收复合增速更高（62.0% vs 39.4%）
Nelnet（耐尔奈特）是总部位于美国内布拉斯加州林肯市的综合性企业集团，核心业务涵盖金融服务领域，主营学生贷款、消费贷款的发放与服务，同时设有投资板块与互联网银行，还持有有线电视及网络服务商Allo Fiber 26%的股权。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NNI vs RGNX — 直观对比
营收规模更大
NNI
是对方的1.1倍
$30.3M
营收增速更快
NNI
高出36.6%
43.0%
净利率更高
NNI
高出393.6%
-221.3%
自由现金流更多
NNI
多$449.5M
$-52.8M
两年增速更快
NNI
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.5M | $30.3M |
| 净利润 | $57.8M | $-67.1M |
| 毛利率 | 50.5% | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 172.3% | -221.3% |
| 营收同比 | 79.6% | 43.0% |
| 净利润同比 | -8.5% | -31.2% |
| 每股收益（稀释后） | $1.62 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NNIRGNX
| Q4 25 | $33.5M | $30.3M | ||
| Q3 25 | $23.2M | $29.7M | ||
| Q2 25 | $26.1M | $21.4M | ||
| Q1 25 | $24.7M | $89.0M | ||
| Q4 24 | $18.7M | $21.2M | ||
| Q3 24 | $16.6M | $24.2M | ||
| Q2 24 | $14.9M | $22.3M | ||
| Q1 24 | $12.8M | $15.6M |
净利润NNIRGNX
| Q4 25 | $57.8M | $-67.1M | ||
| Q3 25 | $106.7M | $-61.9M | ||
| Q2 25 | $181.5M | $-70.9M | ||
| Q1 25 | $82.6M | $6.1M | ||
| Q4 24 | $63.2M | $-51.2M | ||
| Q3 24 | $2.4M | $-59.6M | ||
| Q2 24 | $45.1M | $-53.0M | ||
| Q1 24 | $73.4M | $-63.3M |
毛利率NNIRGNX
| Q4 25 | 50.5% | — | ||
| Q3 25 | 29.6% | — | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 13.7% | 70.2% | ||
| Q3 24 | 0.1% | 48.8% | ||
| Q2 24 | 27.3% | 52.5% | ||
| Q1 24 | 15.3% | 72.6% |
营业利润率NNIRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | 97.7% | -242.1% | ||
| Q3 24 | -13.4% | -256.6% | ||
| Q2 24 | 88.0% | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率NNIRGNX
| Q4 25 | 172.3% | -221.3% | ||
| Q3 25 | 460.5% | -208.3% | ||
| Q2 25 | 694.9% | -331.8% | ||
| Q1 25 | 334.4% | 6.8% | ||
| Q4 24 | 338.2% | -241.3% | ||
| Q3 24 | 14.4% | -246.3% | ||
| Q2 24 | 303.6% | -237.7% | ||
| Q1 24 | 574.4% | -405.4% |
每股收益（稀释后）NNIRGNX
| Q4 25 | $1.62 | $-1.30 | ||
| Q3 25 | $2.94 | $-1.20 | ||
| Q2 25 | $4.97 | $-1.38 | ||
| Q1 25 | $2.26 | $0.12 | ||
| Q4 24 | $1.74 | $-0.99 | ||
| Q3 24 | $0.07 | $-1.17 | ||
| Q2 24 | $1.23 | $-1.05 | ||
| Q1 24 | $1.98 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $296.0M | $230.1M |
| 总债务越低越好 | $7.8B | — |
| 股东权益账面价值 | $3.7B | $102.7M |
| 总资产 | $14.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 2.11× | — |
8季度趋势，按日历期对齐
现金及短期投资NNIRGNX
| Q4 25 | $296.0M | $230.1M | ||
| Q3 25 | $216.4M | $274.2M | ||
| Q2 25 | $225.8M | $323.3M | ||
| Q1 25 | $220.5M | $267.9M | ||
| Q4 24 | $194.5M | $234.7M | ||
| Q3 24 | $219.7M | $255.5M | ||
| Q2 24 | $145.5M | $290.4M | ||
| Q1 24 | $179.7M | $338.7M |
总债务NNIRGNX
| Q4 25 | $7.8B | — | ||
| Q3 25 | $7.8B | — | ||
| Q2 25 | $7.9B | — | ||
| Q1 25 | $8.7B | — | ||
| Q4 24 | $8.3B | — | ||
| Q3 24 | $8.9B | — | ||
| Q2 24 | $9.6B | — | ||
| Q1 24 | $10.6B | — |
股东权益NNIRGNX
| Q4 25 | $3.7B | $102.7M | ||
| Q3 25 | $3.7B | $161.5M | ||
| Q2 25 | $3.6B | $213.7M | ||
| Q1 25 | $3.4B | $274.2M | ||
| Q4 24 | $3.3B | $259.7M | ||
| Q3 24 | $3.3B | $301.4M | ||
| Q2 24 | $3.3B | $348.3M | ||
| Q1 24 | $3.3B | $390.7M |
总资产NNIRGNX
| Q4 25 | $14.1B | $453.0M | ||
| Q3 25 | $13.9B | $525.2M | ||
| Q2 25 | $13.7B | $581.0M | ||
| Q1 25 | $14.2B | $490.9M | ||
| Q4 24 | $13.8B | $466.0M | ||
| Q3 24 | $14.1B | $519.1M | ||
| Q2 24 | $14.5B | $569.4M | ||
| Q1 24 | $15.4B | $629.2M |
负债/权益比NNIRGNX
| Q4 25 | 2.11× | — | ||
| Q3 25 | 2.14× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.48× | — | ||
| Q3 24 | 2.72× | — | ||
| Q2 24 | 2.90× | — | ||
| Q1 24 | 3.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $423.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $396.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 1183.0% | -174.0% |
| 资本支出强度资本支出/营收 | 78.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 7.32× | — |
| 过去12个月自由现金流最近4个季度 | $663.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NNIRGNX
| Q4 25 | $423.0M | $-52.3M | ||
| Q3 25 | $112.4M | $-56.0M | ||
| Q2 25 | $81.8M | $-49.3M | ||
| Q1 25 | $91.2M | $33.6M | ||
| Q4 24 | $662.9M | $-31.6M | ||
| Q3 24 | $137.0M | $-40.5M | ||
| Q2 24 | $133.8M | $-45.5M | ||
| Q1 24 | $211.6M | $-55.5M |
自由现金流NNIRGNX
| Q4 25 | $396.7M | $-52.8M | ||
| Q3 25 | $100.8M | $-56.5M | ||
| Q2 25 | $78.1M | $-49.7M | ||
| Q1 25 | $87.8M | $32.6M | ||
| Q4 24 | $642.0M | $-32.7M | ||
| Q3 24 | $132.6M | $-40.9M | ||
| Q2 24 | $123.1M | $-46.0M | ||
| Q1 24 | $188.3M | $-56.0M |
自由现金流率NNIRGNX
| Q4 25 | 1183.0% | -174.0% | ||
| Q3 25 | 435.0% | -189.9% | ||
| Q2 25 | 299.0% | -232.8% | ||
| Q1 25 | 355.6% | 36.6% | ||
| Q4 24 | 3438.0% | -154.2% | ||
| Q3 24 | 797.9% | -168.9% | ||
| Q2 24 | 829.2% | -206.2% | ||
| Q1 24 | 1473.7% | -358.5% |
资本支出强度NNIRGNX
| Q4 25 | 78.2% | 1.7% | ||
| Q3 25 | 50.4% | 1.7% | ||
| Q2 25 | 14.2% | 1.8% | ||
| Q1 25 | 13.7% | 1.2% | ||
| Q4 24 | 111.9% | 5.1% | ||
| Q3 24 | 26.7% | 1.3% | ||
| Q2 24 | 71.5% | 2.1% | ||
| Q1 24 | 181.7% | 3.6% |
现金转化率NNIRGNX
| Q4 25 | 7.32× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | 1.10× | 5.53× | ||
| Q4 24 | 10.50× | — | ||
| Q3 24 | 57.39× | — | ||
| Q2 24 | 2.97× | — | ||
| Q1 24 | 2.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NNI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
